Tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade

Abstract

Background

Immune checkpoint inhibitors are poised to revolutionize the management of a growing number of malignancies. Unfortunately, the management of steroid-refractory immune mediated adverse events is based on a paucity of randomized data and limited to single center experiences. Our initial experience with the IL-6 receptor antagonist tocilizumab showed clinical improvement in a wide variety of irAEs. As a result, we adopted the use of tocilizumab for the management of steroid refractory irAEs.

Methods

The character and clinical course of irAEs were abstracted from the medical record and analyzed. The dose of tocilizumab was 4 mg/kg given IV over one hour. C-reactive protein was drawn at first nivolumab infusion and at q two weeks (and with irAEs) thereafter. Clinical improvement was defined as either: documentation of resolution of symptoms or hospital discharge within seven days.

Results

Of the initial 87 patients that were treated with nivolumab, 34 required tocilizumab (39.1%). All patients were on corticosteroids. The majority (88.2%) were lung cancer patients. The index grade 3/4 irAE was pneumonitis in 35.3%, serum sickness/SIRS in 35.3%, cerebritis in 14.7% and one case each of hypophysitis, colitis, pancreatitis, hepatitis and immune mediated coagulopathy. Median time between first nivolumab and initiation of tocilizumab was 76 days (range 1–429). There was a statistically significant increase in C-reactive protein from a median of 23 mg/L (range 0.1–238.5) at baseline to 109.3 mg/L (21.5–350.4) at the time of index irAE, followed by a decrease to 19.2 mg/L (0.25–149) after tocilizumab (p < 0.00001). Clinical improvement was noted in 27/34 patients (79.4%). Some patients (52.9%) required a single dose, while 38.2% required two, 8.8% required three and 1 patient required four doses. Twenty-seven doses were given in the inpatient setting (49.1%). Median time to discharge was four days (range 1–27). Seventy-four percent of patients were discharged home. For the 53 doses of tocilizumab that were delivered when infliximab was an option, there was a cost savings of $141,048.72 (WAC) during the 18 month study period.

Conclusions

Tocilizumab may be a therapeutic option for the management of steroid refractory irAEs secondary to immune checkpoint blockade. However, randomized trials are needed to better elucidate the relative efficacy and safety of these agents.

Keywords

C-reactive protein Immune checkpoint inhibitors Immune mediated adverse events nivolumab tocilizumab

Get full access to this article

View all access options for this article.

References

Michot

Bigenwald

Champiat

et al.

Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer 2016; 54: 139–148.

Weber

Yang

Atkins

et al.

Toxicities of Immunotherapy for the practitioner. J Clin Oncol 2015; 33: 2092–2099.

Larkin

Chiarion-Sileni

Gonzalez

et al.

Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 2015; 373: 23–34.

Topalian

Hodi

Brahmer

et al.

Safety, activity, and immune correlates of anti–PD-1 antibody in cancer. N Engl J Med 2012; 366: 2443–2454.

Brahmer

Reckamp

Baas

et al.

Nivolumab versus docetaxel in advanced squamous-cell non–small-cell lung cancer. N Engl J Med 2015; 373: 123–135.

Borghaei

Paz-Ares

Horn

et al.

Nivolumab versus docetaxel in advanced nonsquamous non–small-cell lung cancer. N Engl J Med 2015; 373: 1627–1639.

Champiat

Lambotte

Barreau

et al.

Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper. Ann Oncol 2016; 27: 559–574.

Friedman

Proverbs-Singh

Postow

. Treatment of the immune-related adverse effects of immune checkpoint inhibitors. JAMA Oncol 2016; 2: 1346–1346.

Haratani

Hayashi

Chiba

et al.

Association of immune-related adverse events with nivolumab efficacy in non–small-cell lung cancer. JAMA Oncol. September 2017.

10.

Shoushtari

Friedman

Navid-Azarbaijani

et al.

Measuring toxic effects and time to treatment failure for nivolumab plus ipilimumab in melanoma. JAMA Oncol. August 2017.

11.

Chen

Razak

Bedard

et al.

A systematic review of immune-related adverse event reporting in clinical trials of immune checkpoint inhibitors. Ann Oncol 2015; 26: 1824–1829.

12.

Champiat

Lambotte

Barreau

et al.

Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper. Ann Oncol 2016; 27: 559–574.

13.

ASCO and NCCN to collaborate on guidelines on management of immunotherapy side effects – The ASCO post, www.ascopost.com/issues/march-10-2017/asco-and-nccn-to-collaborate-on-guidelines-on-management-of-immunotherapy-side-effects/ (accessed 1 October 2017).

14.

Naidoo

Wang

Woo

et al.

Pneumonitis in patients treated with anti–programmed death-1/programmed death ligand 1 therapy. J Clin Oncol 2017; 35: 709–717.

15.

Lee

Gardner

Porter

et al.

Current concepts in the diagnosis and management of cytokine release syndrome. Blood 2014; 124: 188–195.

16.

Brudno

Kochenderfer

. Toxicities of chimeric antigen receptor T cells: recognition and management. Blood 2016; 127: 3321–3330.

17.

Sharma

Stroud

CRG

Walker

et al.

Systemic inflammatory response syndrome (SIRS) with immune checkpoint inhibitors. J Clin Oncol 2016; 34: 3061–3061.

18.

Horvat

Adel

Dang

T-O

et al.

Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at Memorial Sloan Kettering Cancer Center. J Clin Oncol 2015; 33: 3193–3198.

19.

Scheller J, Chalaris A, Schmidt-Arras D, et al. The pro- and anti-inflammatory properties of the cytokine interleukin-6. Biochim Biophys Acta – Mol Cell Res 2011; 1813: 878–888. doi:10.1016/J.BBAMCR.2011.01.034.

20.

Davila

Riviere

Wang

et al.

Efficacy and toxicity management of 19-28 z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med 2014; 6: 224ra25–224ra25.

21.

Chang

Daly

Bromberg

. The IL-6 feed-forward loop: a driver of tumorigenesis. Semin Immunol 2014; 26: 48–53.

22.

Laird

BJA

Fallon

Hjermstad

et al.

Quality of life in patients with advanced cancer: differential association with performance status and systemic inflammatory response. J Clin Oncol 2016; 34: 2769–2775.

23.

Ando

Takahashi

Motojima

et al.

Possible role for tocilizumab, an anti-interleukin-6 receptor antibody, in treating cancer cachexia. J Clin Oncol 2013; 31: e69–e72.

24.

Kim

et al.

Oncology Letters 2015; Vol 9., Spandidos Publications,, 2015.

25.

Shinriki

Jono

Ota

et al.

Humanized anti-interleukin-6 receptor antibody suppresses tumor angiogenesis and in vivo growth of human oral squamous cell carcinoma. Clin Cancer Res 2009; 15: 5426–5434.

26.

Rossi

J-F

Z-Y

Jourdan

et al.

Interleukin-6 as a therapeutic target. Clin Cancer Res 2015; 21: 1248–1257.

27.

Ascierto

Simeone

Sileni

et al.

Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohort. J Transl Med 2014; 12: 116–116.

28.

Chung

Mirakhur

Chan

et al.

Cetuximab-induced anaphylaxis and IgE specific for galactose-α-1,3-galactose. N Engl J Med 2008; 358: 1109–1117.

29.

O’Neil

Allen

Spigel

et al.

High incidence of cetuximab-related infusion reactions in Tennessee and North Carolina and the association with atopic history. J Clin Oncol 2007; 25: 3644–3648.

30.

Commins

James

Kelly

et al.

The relevance of tick bites to the production of IgE antibodies to the mammalian oligosaccharide galactose-α-1,3-galactose. J Allergy Clin Immunol 2011; 127: 1286–1293.e6.

31.

Weber

Hodi

Wolchok

et al.

Safety profile of nivolumab monotherapy: a pooled analysis of patients with advanced melanoma. J Clin Oncol 2017; 35: 785–792.